drugset / Trial / NCT03683667

Protein Plus: Improving Infant Growth Through Diet and Enteric Health

NCT03683667 ↗

RandomizedFactorialQuadruple-blindPrevention

Summary

This cluster-randomized controlled trial is designed to address linear growth faltering in 6-12-mo-old Bangladesh infants through a proof-of-concept package of interventions to a) increase intake of high quality protein and b) control enteric pathogens.

Timeline

Start
2018-09-23
Primary completion
2020-03-19
Completion
2020-03-24

Outcome

Missed primary endpoint

paper The intervention did not have a statistically significant effect on mean LAZ (β: 0.05, 95% confidence interval [CI]: -0.01, 0.10) or stunting prevalence PMID 38759886 ↗

paper provided with or without presumptive treatment for enteric pathogens, did not improve linear growth from 6 to 12 mo of age. PMID 39788294 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 10 mg/kg Oral